COSCIENS Biopharma Inc. has seen a significant drop in its stock price, which has raised concerns among investors.
In yesterday's trading session, COSCIENS Biopharma Inc. (CSCI.TO) experienced a 2.93% decline, closing at CA$9.60. This drop comes as the company faces scrutiny over its financial health and recent operational updates.
Advertisement
COSCIENS Biopharma Inc.
CSCI.TO
CSCI.TO
COSCIENS Biopharma Inc.
WealthAwesomeMarket cap
$9.57M
52W high
$14.80
52W low
$3.30
1W change
+9.71%
Beta
1.80
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CSCI's historical volatility
30-Day Vol
66.2%
Annualized
90-Day Vol
335.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$11.48
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$10.19 | C$8.11 – C$12.80 |
| 60 trading days | C$10.81 | C$7.83 – C$14.94 |
| 90 trading days | C$11.48 | C$7.73 – C$17.05 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious about COSCIENS Biopharma's recent performance and consider the potential implications of its ongoing financial adjustments.
CSCI.TO fell 2.93% yesterday
COSCIENS Biopharma Inc. now has a market cap of CA$9,573,303, highlighting the challenges it faces in maintaining investor confidence.
Bull case
Despite the recent decline, COSCIENS Biopharma has improved its cash position and reduced net losses, which could indicate a potential recovery in the future.
Bear case
The recent stock performance raises concerns about the company's financial stability and its ability to manage its debt effectively.
Advertisement
Understanding the Decline
The 2.93% drop in COSCIENS Biopharma's stock price reflects investor worries about the company's recent financial announcements. With a market cap of CA$9,573,303, the company is under scrutiny regarding its financial management. Investors are particularly cautious due to the absence of positive news to offset the decline.
Future Outlook
As COSCIENS Biopharma works through its financial challenges, investors should pay attention to upcoming announcements and financial reports. The company's efforts to improve its cash position and reduce net losses may offer some hope for recovery. However, the recent stock performance suggests that careful evaluation is necessary before making any investment decisions. For more insights on COSCIENS Biopharma, check out our detailed analysis on CSCI.TO.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
